Dr. Scott Dindot Discusses Genomic Imprinting
«Genomic imprinting affects the manner in which mutations in UBE3A produce symptoms of Angelman Syndrome» says FIRE team member and Associate Professor Dr.
«Genomic imprinting affects the manner in which mutations in UBE3A produce symptoms of Angelman Syndrome» says FIRE team member and Associate Professor Dr.
Is it possible to “turn on” or express the UBE3A gene? Dr. David Segal from the University of California Davis talks about the FIRE funded project his la
“It has been our hope from day one that the pharmaceutical industry would recognize the promise for developing therapeutics for Angelman Syndrome, we are t
Ovid Therapeutics announces the first ever sponsored clinical trial for Angelman Syndrome. You first heard about Gabaxadol from Dr. Matthew During at the FAS